June 1, 2019 “Chemotherapy has been our only option for many years. These results introduce a potential alternative in pembrolizumab that comes with fewer side effects, and importantly, for some it can greatly extend survival. This opens the door to helping patients live longer and better lives,” said Richard L. Schilsky, MD, FACP, FSCT, FASCO,...
Pro zobrazení tohoto obsahu je třeba být přihlášen.